At a diabetes conference in Milan, researchers presented evidence that a once-daily oral medication called orforglipron produces consistent and meaningful weight loss in women across all stages of the menopause transition — a biological threshold long associated with accelerating weight gain and metabolic vulnerability. The findings, drawn from two large clinical trials, suggest that this class of drug may work independently of estrogen status, offering a potential tool for a life stage when the body has historically resisted intervention. In the broader arc of women's health, this represents
Oral GLP-1 drug shows consistent weight loss across menopause stages
The drug works equally well before, during, and after menopause
Mark
So this is about a new drug, or a new use for an existing drug?
Mimi
It's an existing class—GLP-1 receptor agonists—but orforglipron is the specific oral version being studied here. It's a daily pill, not an injection, which matters for how people actually take it.
Luke
And these are Eli Lilly's own trials, right? So we should be careful about how we weight that.
Mimi
Yes, both ATTAIN-1 and ATTAIN-2 are company-sponsored. But the data itself—the 14 percent weight loss, the 83 percent hitting the 5 percent threshold—those are the numbers they're presenting at a major diabetes conference.
Mark
Why does menopause matter so much for this story?
Mimi
Because obesity gets worse during menopause when estrogen drops. If a drug works equally well before, during, and after menopause, it's saying the drug doesn't depend on hormones to work. It's a bigger claim than just "this drug causes weight loss."
Luke
But we don't know the mechanism from this reporting. We know the effect was consistent, but not why.
Mimi
That's fair. The mechanism isn't explained in what was presented.
Mark
What about side effects? Are those mentioned?
Luke
Not in this material. We have efficacy data but nothing on tolerability or adverse events.
Mimi
That's a real gap. For a drug like this, people want to know what it costs in terms of how you feel.
Mark
So what's the actual news here—is it that the drug works, or that it works equally across menopause stages?
Mimi
The second one. GLP-1s already work for weight loss. The news is that menopause doesn't seem to blunt the effect.
O Pulso
- Menopause has long been a metabolic turning point where weight gain accelerates and conventional interventions lose their footing — orforglipron now challenges that assumption directly.
- Across 72 weeks and hundreds of participants sorted by menopausal stage, the drug produced up to 14% body weight reduction with striking uniformity, regardless of where women stood hormonally.
- Up to 83% of women on orforglipron crossed the clinically meaningful 5% weight-loss threshold, compared to just 30% on placebo — a gap that signals genuine pharmacological effect rather than statistical noise.
- Waist circumference shrank by nearly five inches in some groups, and more women shifted into healthier waist-to-height ratio categories, suggesting the drug reshapes not just weight but how the body distributes fat.
- The consistency of results across premenopausal, perimenopausal, and postmenopausal women points toward a mechanism that operates independently of estrogen, potentially reframing how clinicians approach obesity treatment in midlife and beyond.
At a diabetes conference in Milan, researchers presented evidence that a once-daily oral medication called orforglipron produces consistent and meaningful weight loss in women across all stages of the menopause transition — a biological threshold long associated with accelerating weight gain and metabolic vulnerability. The findings, drawn from two large clinical trials, suggest that this class of drug may work independently of estrogen status, offering a potential tool for a life stage when the body has historically resisted intervention. In the broader arc of women's health, this represents a quiet but significant shift: the possibility that hormonal circumstance need not determine metabolic fate.
At this week's European Association for the Study of Diabetes conference in Milan, researchers shared findings that a daily oral GLP-1 medication produced consistent weight loss in women regardless of their menopausal stage — a result with particular significance given that menopause is well understood as a moment when weight gain becomes easier and weight loss harder.
The drug, orforglipron, was evaluated through two large clinical trials — ATTAIN-1, which enrolled women with excess weight or obesity but without diabetes, and ATTAIN-2, which included women with both obesity and type 2 diabetes. Both trials, conducted by Eli Lilly, tracked participants for 72 weeks and sorted them by menopausal stage: premenopausal, perimenopausal, and postmenopausal.
The results held steady across all three groups. Women on orforglipron lost up to 14% of their body weight, with waist circumference reductions reaching nearly five inches. Eighty-three percent of women on the active drug achieved at least 5% body weight loss, compared to 30% on placebo. Researchers also tracked shifts in waist-to-height ratio, finding that more women on orforglipron moved into healthier categories — suggesting the drug influences not just total weight but fat distribution.
The uniformity of the effect is what makes the findings notable. If orforglipron can produce the same results in postmenopausal women as in those still in their reproductive years, it implies the drug's mechanism operates independently of estrogen — potentially opening a meaningful path forward for women in the life stage when managing weight has historically been most difficult.
Researchers presenting findings this week at the European Association for the Study of Diabetes conference in Milan have new evidence that a daily oral weight-loss medication works equally well for women regardless of where they stand in the menopause transition. The drug, orforglipron, produced consistent weight reductions of up to 14 percent across women who were premenopausal, perimenopausal, and postmenopausal—a finding that matters because obesity tends to worsen during menopause when estrogen levels drop.
Orforglipron is a GLP-1 receptor agonist, a class of medication originally developed for type 2 diabetes that has shown powerful effects on weight. The analysis comes from two large clinical trials called ATTAIN-1 and ATTAIN-2, both conducted by researchers at Eli Lilly and Company, which manufactures the drug. ATTAIN-1 enrolled women with excess weight or obesity but without diabetes; ATTAIN-2 included women with both obesity and type 2 diabetes. In both studies, women were sorted by menopausal stage and tracked for 72 weeks.
The participant groups were substantial: between 142 and 225 women in each menopausal category received either orforglipron or a placebo. Researchers measured not just overall weight loss but also changes in waist circumference and waist-to-height ratio—metrics that capture how the body redistributes fat, which matters for health outcomes independent of the number on a scale. They also tracked how many women hit specific weight-loss milestones: losing at least 5 percent, 10 percent, 15 percent, or 20 percent of their starting weight.
The results were striking in their consistency. Women taking orforglipron lost similar amounts of weight whether they were in their reproductive years, transitioning through menopause, or past it. Waist circumference shrank by up to 12.5 centimeters—nearly five inches—across all three groups in both trials. When it came to hitting the 5 percent weight-loss threshold, 83 percent of women on orforglipron achieved it, compared to just 30 percent of those on placebo. More women on the active drug also moved into lower waist-to-height ratio categories, suggesting the medication helped reshape where the body carries weight.
The uniformity of the effect across menopausal stages is the key takeaway here. Menopause has long been understood as a metabolic inflection point for women—the hormonal shift makes weight gain easier and weight loss harder. If orforglipron can overcome that biological headwind and produce the same weight reduction in postmenopausal women as in younger women, it suggests the drug's mechanism works independently of estrogen status. That opens a door for women in a life stage when weight management has historically been most difficult.
Citações Notáveis
Obesity, a chronic, progressive disease, is exacerbated by estrogen deficiency during menopause— Study researchers
Quer a matéria completa?
Leia o original em Medical Xpress ↗